We discussed some of the major challenges for PRAME-based immunotherapy that need to be addressed, including the intra- and inter-tumor heterogeneous expression of PRAME and the potential role of PRAME in the upregulation of immune evasion mechanisms. The gene discussed is PRAME; the disease is neoplasm.